Post-approval fate of pharmaceutical companies

Michael S. Kinch

Research output: Contribution to journalShort surveypeer-review

1 Scopus citations


For a fortunate subset of pharmaceutical companies, a regulatory approval is the culmination of massive investment in time, work and money. What happens next? Some companies proceed to build a pipeline and obtain additional approvals. Others do not. In this present report, post-approval fate is evaluated and it was found that most companies are ultimately acquired. A subset achieved a second approval six-to-eight years after the first approval, whereas a shrinking subset, designated as 'singlets', remains active in drug discovery with only a single approval. The likelihood that a company will remain a singlet or be acquired relates to therapeutic indication, with oncology associated with increased acquisition potential and infectious-disease-based companies being less commonly acquired.

Original languageEnglish
Pages (from-to)170-174
Number of pages5
JournalDrug Discovery Today
Issue number2
StatePublished - Feb 2015


Dive into the research topics of 'Post-approval fate of pharmaceutical companies'. Together they form a unique fingerprint.

Cite this